{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:55:49Z","timestamp":1784883349113,"version":"3.55.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":4113,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1111\/j.1538-7836.2011.04432.x","type":"journal-article","created":{"date-parts":[[2011,7,5]],"date-time":"2011-07-05T17:27:26Z","timestamp":1309886846000},"page":"1705-1712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":137,"title":["Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents"],"prefix":"10.1016","volume":"9","author":[{"given":"M.","family":"LEVI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"EERENBERG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.W.","family":"KAMPHUISEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0010","doi-asserted-by":"crossref","first-page":"110S","DOI":"10.1378\/chest.08-0652","article-title":"Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Hirsh","year":"2008","journal-title":"Chest"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0015","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1056\/NEJMra067742","article-title":"Prevention and treatment of major blood loss","volume":"356","author":"Mannucci","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0020","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1474-4422(06)70685-8","article-title":"Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial","volume":"6","author":"Algra","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11739-008-0201-8","article-title":"Emergency reversal of antithrombotic treatment","volume":"4","author":"Levi","year":"2009","journal-title":"Intern Emerg Med"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0035","first-page":"68","article-title":"Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management","volume":"68","author":"Levi","year":"2010","journal-title":"Neth J Med"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0040","doi-asserted-by":"crossref","first-page":"257S","DOI":"10.1378\/chest.08-0674","article-title":"Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Schulman","year":"2008","journal-title":"Chest"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0045","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(96)01109-9","article-title":"Bleeding complications of oral anticoagulant treatment: an inception\u2010cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy","volume":"348","author":"Palareti","year":"1996","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0050","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.clinthera.2004.09.002","article-title":"Results of an open\u2010label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic","volume":"26","author":"Abdelhafiz","year":"2004","journal-title":"Clin Ther"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0055","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1445-5994.2001.00071.x","article-title":"Outcomes in the management of atrial fibrillation: clinical trial results can apply in practice","volume":"31","author":"Jackson","year":"2001","journal-title":"Intern Med J"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0060","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1182\/blood-2007-11-123711","article-title":"Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based","volume":"111","author":"Levi","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0065","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJM199002153220703","article-title":"Trial of different intensities of anticoagulation in patients with prosthetic heart valves","volume":"322","author":"Saour","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0070","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.jacc.2003.07.029","article-title":"The optimal intensity of vitamin K antagonists in patients with mechanical heart valves: a meta\u2010analysis","volume":"42","author":"Vink","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0075","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/0003-4819-120-11-199406010-00001","article-title":"Risk factors for intracranial hemorrhage in outpatients taking warfarin","volume":"120","author":"Hylek","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0080","doi-asserted-by":"crossref","first-page":"381S","DOI":"10.1378\/chest.08-0656","article-title":"Prevention of venous thromboembolism: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Geerts","year":"2008","journal-title":"Chest"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0085","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.0007-1323.2001.01800.x","article-title":"Meta\u2010analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery","volume":"88","author":"Mismetti","year":"2001","journal-title":"Br J Surg"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0090","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1001\/archinte.159.17.2029","article-title":"Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times","volume":"159","author":"Anand","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0095","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0100","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00002512-199914040-00005","article-title":"Safety of treatment with oral anticoagulants in the elderly. A systematic review","volume":"14","author":"Hutten","year":"1999","journal-title":"Drugs Aging"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0105","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-141-10-200411160-00005","article-title":"Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation","volume":"141","author":"Fang","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0110","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000015958","article-title":"Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: A meta\u2010analysis and hypothesis","volume":"9","author":"Hart","year":"1999","journal-title":"Cerebrovasc Dis"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0115","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-143-4-200508160-00005","article-title":"Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta\u2010analysis with estimates of risk and benefit","volume":"143","author":"Rothberg","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0120","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1136\/bmj.38947.697558.AE","article-title":"Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case\u2010control study","volume":"333","author":"Hallas","year":"2006","journal-title":"BMJ"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.0306-5251.2001.01220.x","article-title":"Upper gastrointestinal bleeding among users of NSAIDs: a population\u2010based cohort study in Denmark","volume":"53","author":"Mellemkjaer","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0130","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/archinte.165.2.189","article-title":"Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX\u20102 inhibitors","volume":"165","author":"Battistella","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0135","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0140","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/j.1538-7836.2006.01986.x","article-title":"Treatment of coumarin\u2010associated coagulopathy: a systematic review and proposed treatment algorithms","volume":"4","author":"Dentali","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0145","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/0003-4819-150-5-200903030-00005","article-title":"Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin","volume":"150","author":"Crowther","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0150","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7326\/0003-4819-137-4-200208200-00009","article-title":"Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin\u2010associated coagulopathy. A randomized, controlled trial","volume":"137","author":"Crowther","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0155","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1001\/archinte.163.20.2469","article-title":"Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study","volume":"163","author":"Lubetsky","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0160","first-page":"857","article-title":"Management of coumarin\u2010associated coagulopathy in the non\u2010bleeding patient: a systematic review","volume":"89","author":"Dentali","year":"2004","journal-title":"Haematologica"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0165","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1538-7836.2008.02904.x","article-title":"Prothrombin complex concentrate (Beriplex P\/N) for emergency anticoagulation reversal: a prospective multinational clinical trial","volume":"6","author":"Pabinger","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0170","doi-asserted-by":"crossref","first-page":"141S","DOI":"10.1378\/chest.08-0689","article-title":"Parenteral anticoagulants: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Hirsh","year":"2008","journal-title":"Chest"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0175","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0049-3848(87)90343-4","article-title":"Protamine reversal of anticoagulation achieved with a low molecular weight heparin. The effects on eicosanoids, clotting and complement factors","volume":"48","author":"Lindblad","year":"1987","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0180","first-page":"139","article-title":"Partial reversal of low molecular weight heparin (PK 10169) anti\u2010Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation","volume":"16","author":"Massonnet\u2010Castel","year":"1986","journal-title":"Haemostasis"},{"issue":"Suppl 2","key":"10.1111\/j.1538-7836.2011.04432.x_bb0185","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-2002-32315","article-title":"Treatment of symptomatic venous thromboembolism: improving outcomes","volume":"28","author":"Buller","year":"2002","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0190","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1182\/blood-2007-10-120543","article-title":"Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents","volume":"111","author":"Crowther","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0195","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2003.04811.x","article-title":"Recombinant factor VIIa reverses the anticoagulant effect of the long\u2010acting pentasaccharide idraparinux in healthy volunteers","volume":"124","author":"Bijsterveld","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0200","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/01.CIR.0000038501.87442.02","article-title":"Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers","volume":"106","author":"Bijsterveld","year":"2002","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0205","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1182\/blood-2010-06-288522","article-title":"Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives","volume":"117","author":"Bianchini","year":"2011","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0210","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1538-7836.2010.04100.x","article-title":"Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis","volume":"9","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0215","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejim.2004.11.009","article-title":"New antithrombotics in the treatment of thromboembolic disease","volume":"16","author":"Levi","year":"2005","journal-title":"Eur J Intern Med"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0220","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"Treatment of proximal deep\u2010vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59\u20107939): the ODIXa\u2010DVT (Oral Direct Factor Xa Inhibitor BAY 59\u20107939 in Patients With Acute Symptomatic Deep\u2010Vein Thrombosis) study","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0225","first-page":"1020","article-title":"Apixaban, an oral, direct inhibitor of activated Factor Xa","volume":"9","author":"Shantsila","year":"2008","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0230","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ahj.2009.11.025","article-title":"Rivaroxaban\u2010once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study","volume":"159","year":"2010","journal-title":"Am Heart J"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0235","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0240","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0245","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0250","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1538-7836.2008.03054.x","article-title":"Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose\u2010ranging study","volume":"6","author":"Buller","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0255","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2008-05-160143","article-title":"A dose\u2010ranging study evaluating once\u2010daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein\u2010DVT Dose\u2010Ranging Study","volume":"112","author":"Buller","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0260","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS\u2010TIMI 46): a randomised, double\u2010blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0265","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial","volume":"119","author":"Alexander","year":"2009","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0270","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo\u2010controlled, cross\u2010over study in healthy subjects","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0275","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1160\/TH10-05-0328","article-title":"Clinical laboratory measurement of direct factor Xa inhibitors: anti\u2010Xa assay is preferable to prothrombin time assay","volume":"104","author":"Barrett","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0280","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1538-7836.2010.04098.x","article-title":"Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays","volume":"9","author":"Hillarp","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0285","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/hc0802.104331","article-title":"Direct thrombin inhibitors in acute coronary syndromes: present and future","volume":"105","author":"Weitz","year":"2002","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0290","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nrd2622","article-title":"Dabigatran etexilate","volume":"7","author":"Eriksson","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0295","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double\u2010blind, non\u2010inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0300","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1160\/TH03-09-0605","article-title":"Effect of recombinant factor VIIa on melagatran\u2010induced inhibition of thrombin generation and platelet activation in healthy volunteers","volume":"91","author":"Woltz","year":"2004","journal-title":"Thromb Haemos"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0305","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1160\/TH10-06-0342","article-title":"Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays","volume":"105","author":"Lindahl","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0310","doi-asserted-by":"crossref","first-page":"199S","DOI":"10.1378\/chest.08-0672","article-title":"Antiplatelet drugs: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Patrono","year":"2008","journal-title":"Chest"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0315","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/B:THRO.0000036025.07348.f1","article-title":"The efficacy and safety of perioperative antiplatelet therapy","volume":"17","author":"Merritt","year":"2004","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0320","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood.V90.7.2515","article-title":"Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20\u2003years","volume":"90","author":"Mannucci","year":"1997","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0325","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0330","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST\u2010segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0335","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1056\/NEJMp0806848","article-title":"Prasugrel in clinical practice","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0340","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","article-title":"Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST\u2010elevation myocardial infarction (TRITON\u2010TIMI 38): double\u2010blind, randomised controlled trial","volume":"373","author":"Montalescot","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0345","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0350","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0355","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0360","first-page":"334","volume":"69","author":"Grines","year":"2007","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0365","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1538-7836.2006.02245.x","article-title":"Normalization of platelet reactivity in clopidogrel\u2010treated subjects","volume":"5","author":"Vilahur","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04432.x_bb0370","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/CH-2008-1092","article-title":"Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel","volume":"39","author":"Leithauser","year":"2008","journal-title":"Clin Hemorheol Microcirc"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2011.04432.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622071288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622071288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2011.04432.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:56:57Z","timestamp":1761533817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622071288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":73,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S1538783622071288"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04432.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04432.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}